LONDON – Targeted protein degradation (TPD) specialist Amphista Therapeutics Ltd. has delivered yet another demonstration of investor interest in the field, closing a $53 million series B.
Only four years after its foundation, Acepodia Inc. raised $47 million in a series B financing round. The funds will help the oncology company move its first cell therapy candidate to phase II trials, while expanding its research and development activities with other products from its tech platform.
LONDON – Exevir Bio NV added a further €15 million (US$17.9 million) to close its series A round at €42 million, providing the means to take its nanobody therapy for treating COVID-19 infection through to registration.
Elevatebio LLC, a provider of infrastructure, expertise and investment for a growing roster of cell and gene therapy companies, has raised $525 million in series C financing to advance its work. Matrix Capital Management led the round, joined by new investors Softbank Vision Fund 2 and Fidelity Management and Research Co. Existing investors also joined in.